A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

TempraMed’s VIVI Cap 1 Can Change the Way People Who Inject Insulin Live their Lives

TempraMed is creating easy to use, hassle free solutions that save patients lives by protecting them from damaged medications. TempraMed’s products provide the last mile control management for injectable and temperature sensitive pharmaceuticals, helping patients to manage and control their medications, enabling them to live safer and more spontaneous lives.

TempraMed’s recently launched VIVI Cap 1 is an easy-to-use reusable insulin pen cap that keeps diabetes insulin at a safe temperature 24/7 365 days a year, for years on end without need for any user intervention. The product is FDA registered and CE marked.

Insulin is a protein that spoils and degrades in the wrong temperature conditions. From the point of manufacturing up until it is used, insulin needs to be kept between 36° to 46°F. During use, insulin does not have to be refrigerated but it should stay below 86°F and should not freeze. Insulin must be protected from such exposure.

Injecting insulin that has broken down due to time or temperature, results in poor blood sugar control, and in time can lead to increased dosages and sometimes hospitalization for stabilization.

The VIVI Cap 1 shields insulin in-use from potential temperature damage. Thus, reducing the risk of using damaged insulin and wasting money from discarded insulin that might have been compromised.

Mr. Ron Nagar, TempraMed CEO and Founder, stated “After spending years recognizing the endless struggle that people with diabetes have to gain control over blood glucose levels, I noticed that those on insulin, take it for granted that insulin is always the same and at its best. But sadly, that is not the reality, so in order to protect the insulin without adding any hassle we developed this unique device and made it available for all.”

VIVI Cap uses a unique patented combination of special insulation with “self-regenerating” heat absorbing material and control electronics, this enables the device to operate for years without requiring any user attention or handling. There are no power requirements, no charging and no preliminary preparations needed. For people spending their working days outdoors, there has not been an alternative hassle-free solution that can be used every day to protect insulin from spoiling.

 

SourceTempraMed
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy